Minaris Regenerative Medicine Co., Ltd.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Minaris Regenerative Medicine Co., Ltd. - overview
Established
2018
Location
Yokohama, Kanagawa, Japan
Primary Industry
Biotechnology
About
Based in Yokohama, Japan, and founded in 2018, Minaris Regenerative Medicine Co. , Ltd. (MRJ), formerly named Showa Denko Materials Co. , Ltd.
, is involved in the provision of services that cover the development, clinical, and commercial manufacturing phases of gene and cell-based treatments for conditions such as cancer, genetic disorders, and other chronic diseases. The firm was initially founded as Hitachi Chemical Co. , Ltd. in 2018.
In September 2024, Altaris announced that it has signed definitive agreements to fully acquire Minaris Regenerative Medicine Co. , Ltd. from Resonac Holdings Corporation. Minaris Regenerative Medicine is a global company that develops and manufactures cell and gene therapy products.
The company offers both clinical and commercial manufacturing services from locations in the U. S. , Europe, and Asia. Minaris works closely with clients, such as pharmaceutical companies and academic institutions, to address the specific needs.
The company's goal is to improve society's health through therapies, and highlights to focus on advancing medical care.
Primary Industry
Biotechnology
Sub Industries
Consulting Services, Molecular Science, Genetics & Gene Therapy, Biopharmaceuticals
Website
www.rm.minaris.com
Verticals
Manufacturing
Total Amount Raised
Subscriber access only
Minaris Regenerative Medicine Co., Ltd. - financials
| Fiscal Year Ended | Dec 31, 2022 |
|---|---|
| Revenue (USD) | - |
| % Revenue Growth (YoY) | - |
| EBITDA (USD) | - |
| Operating Income (USD) | - |
| Operating Margin | - |
| % EBITDA Margin | - |
| NET Income (USD) | - |
| % Net Margin | - |
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.